IRADIMED CORPORATION Announces Board Transition: Anthony Vuoto Retires, Joe Kiani Appointed as New Director
IRADIMED CORPORATION (NASDAQ: IRMD), a leader in MRI-compatible patient monitoring and infusion systems, announced key changes to its Board of Directors. Anthony Vuoto, who served as director since 2016, has retired effective August 27, 2025. The company has appointed Joe Kiani, founder of Masimo Corporation, as his replacement effective September 2, 2025.
Kiani, a distinguished medical technology innovator with over 500 patents or patent applications, will serve on the Board's audit committee and as chairman of the compensation committee. He brings extensive experience from his roles as former Chairman and CEO of Masimo (1989-2024), current CEO of Willow Laboratories and Like Minded Labs, and board member of CDX Medical Technologies.
IRADIMED CORPORATION (NASDAQ: IRMD), leader nelle soluzioni di monitoraggio paziente e somministrazione infusionale compatibili con la risonanza magnetica, ha annunciato modifiche nel suo Consiglio di Amministrazione. Anthony Vuoto, membro del Consiglio dal 2016, è andato in pensione con effetto dal 27 agosto 2025. In sua sostituzione, la società ha nominato Joe Kiani, fondatore di Masimo Corporation, con decorrenza dal 2 settembre 2025.
Kiani, noto innovatore nel settore delle tecnologie medicali con oltre 500 brevetti o domande di brevetto, entrerà a far parte del comitato revisione dei conti del Consiglio e assumerà la presidenza del comitato per le retribuzioni. Porta con sé una vasta esperienza maturata come ex Presidente e CEO di Masimo (1989-2024), attuale CEO di Willow Laboratories e Like Minded Labs, e membro del consiglio di CDX Medical Technologies.
IRADIMED CORPORATION (NASDAQ: IRMD), líder en sistemas de monitorización de pacientes y de infusión compatibles con resonancia magnética, anunció cambios en su Junta Directiva. Anthony Vuoto, que ocupaba el cargo de director desde 2016, se jubiló con efecto el 27 de agosto de 2025. La compañía nombró a Joe Kiani, fundador de Masimo Corporation, como su reemplazo a partir del 2 de septiembre de 2025.
Kiani, un destacado innovador en tecnología médica con más de 500 patentes o solicitudes de patente, formará parte del comité de auditoría de la Junta y será presidente del comité de compensación. Aporta amplia experiencia por sus roles como ex presidente y CEO de Masimo (1989-2024), actual CEO de Willow Laboratories y Like Minded Labs, y miembro del consejo de CDX Medical Technologies.
IRADIMED CORPORATION (NASDAQ: IRMD), MRI 호환 환자 모니터링 및 주입 시스템 분야의 선도 기업이 이사회 주요 변동을 발표했습니다. 2016년부터 이사로 재직한 Anthony Vuoto는 2025년 8월 27일부로 은퇴했습니다. 회사는 그의 후임으로 Masimo Corporation의 창립자 Joe Kiani를 2025년 9월 2일부로 임명했습니다.
Kiani는 500개 이상의 특허 또는 특허 출원을 보유한 뛰어난 의료기술 혁신가로서, 이사회의 감사위원회 위원과 보상위원회 위원장으로 활동할 예정입니다. 그는 Masimo의 전 회장 및 CEO(1989–2024), 현재 Willow Laboratories와 Like Minded Labs의 CEO, CDX Medical Technologies의 이사회 멤버로서의 폭넓은 경험을 가져옵니다.
IRADIMED CORPORATION (NASDAQ: IRMD), spécialiste des systèmes de surveillance des patients et d'infusion compatibles avec l'IRM, a annoncé des changements au sein de son conseil d'administration. Anthony Vuoto, administrateur depuis 2016, a pris sa retraite avec effet au 27 août 2025. La société a nommé Joe Kiani, fondateur de Masimo Corporation, comme son remplaçant à compter du 2 septembre 2025.
Kiani, un innovateur reconnu en technologies médicales titulaire de plus de 500 brevets ou demandes de brevet, siégera au comité d'audit du conseil et présidera le comité des rémunérations. Il apporte une vaste expérience issue de ses fonctions d'ancien président et CEO de Masimo (1989–2024), de son rôle actuel de CEO de Willow Laboratories et Like Minded Labs, et de son poste au conseil d'administration de CDX Medical Technologies.
IRADIMED CORPORATION (NASDAQ: IRMD), ein führender Anbieter von MRT‑kompatiblen Patientenmonitoren und Infusionssystemen, hat wesentliche Änderungen in seinem Vorstand bekanntgegeben. Anthony Vuoto, der seit 2016 im Vorstand war, ist mit Wirkung vom 27. August 2025 in den Ruhestand getreten. Das Unternehmen hat Joe Kiani, Gründer der Masimo Corporation, mit Wirkung zum 2. September 2025 als Nachfolger berufen.
Kiani, ein renommierter Innovator im Bereich Medizintechnik mit mehr als 500 Patenten oder Patentanmeldungen, wird dem Prüfungsausschuss des Vorstands angehören und den Vergütungsausschuss als Vorsitzender leiten. Er bringt umfangreiche Erfahrung mit aus seinen Rollen als ehemaliger Chairman und CEO von Masimo (1989–2024), als derzeitiger CEO von Willow Laboratories und Like Minded Labs sowie als Vorstandsmitglied von CDX Medical Technologies.
- Appointment of highly experienced medical technology innovator Joe Kiani with over 500 patents
- Strategic addition of former Masimo CEO brings valuable industry expertise to the board
- Continuity maintained with immediate replacement of retiring board member
- Loss of long-term director Anthony Vuoto's experience and historical knowledge
ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed” or the “Company”) (NASDAQ: IRMD), a leader in innovative medical devices for Magnetic Resonance Imaging (“MRI”)-compatible patient monitoring and infusion systems, today announced a Board of Directors (the “Board”) transition. Anthony Vuoto has retired from his position as a director, effective August 27, 2025, after deciding it is time to step away following many years of dedicated service. Effective September 2, 2025, the Board has appointed Joe Kiani, Masimo founder and renowned medical technology innovator and entrepreneur, to fill the vacancy on the Board.
Anthony Vuoto served as a director of Iradimed since 2016, providing valuable strategic guidance during a period of significant growth and innovation for the Company. The Board and management express their gratitude for Mr. Vuoto’s contributions and wish him success in his future endeavors.
“We are profoundly grateful for Tony’s leadership and commitment to Iradimed over the past decade,” said Roger Susi, President and Chief Executive Officer of Iradimed. “His insights have been invaluable, and we respect his decision to step away after many years of impactful service.”
Joining the Board is Joe Kiani, an industry pioneer with a distinguished track record in medical technology. Mr. Kiani is the founder of Masimo Corporation, where he served as Chairman and CEO from 1989 until 2024, growing the company into a global leader in non-invasive patient monitoring technologies, particularly pulse oximetry. Mr. Kiani is also the CEO of Willow Laboratories, a health and wellness innovator, and Like Minded Labs, a company focused on advanced video technologies, and he serves on the Board of Directors of CDX Medical Technologies, an early-stage respiratory care company. With over 500 patents or patent applications and a reputation for driving innovation, Mr. Kiani brings critical expertise to the Board.
“We are thrilled to welcome Joe Kiani to our Board,” said Mr. Susi. “Joe’s visionary leadership and deep expertise in medical technology will be invaluable as we continue to advance our mission of delivering innovative, MRI-compatible solutions to improve patient care.”
Mr. Kiani’s Board appointment is effective September 2, 2025, and he will serve on the Board’s audit committee and chairman of the compensation committee, helping to guide Iradimed’s growth in the medical device sector.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in developing innovative MRI compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.
We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI-compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from the critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and an optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
For more information, please visit www.iradimed.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, that address activities that the Company assumes, plans, expects, believes, intends, projects, indicates, estimates or anticipates (and other similar expressions) will, should, or may occur in the future are forward-looking statements. The forward-looking statements are based on management’s current belief, based on currently available information, as to the outcome and timing of future events. The forward-looking statements involve risks and uncertainties, including, among others, that our business plans may change as circumstances warrant.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made, which reflect management’s current estimates, projections, expectations, or beliefs, and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to; potential disruptions in our limited supply chain for our products; the Company’s ability to receive U.S. Food and Drug Administration (“FDA”) 510(k) clearance for new products and product candidates; unexpected costs, delays or diversion of management’s attention associated with the design, manufacturing or sale of new products; the Company’s ability to implement successful sales techniques for existing and future products and evaluate the effectiveness of its sales techniques; additional actions, warnings or requests from the FDA or other regulatory bodies; our significant reliance on a limited number of products; a reduction in international distribution; actions of the FDA or other regulatory bodies that could delay, limit or suspend product development, manufacturing or sales; the effect of recalls, patient adverse events or deaths on our business; difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services; and changes in laws and regulations or in the interpretation or application of laws or regulations.
Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of the Company’s control that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties, assumptions and other important factors include, but are not limited to, those included in Part II, Item 1A, “Risk Factors” of the Company’s Quarterly Reports on Form 10-Q, and Part I, Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as those otherwise described or updated from time to time in our other filings with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Media Contact:
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
FAQ
Who is the new board member at IRADIMED CORPORATION (NASDAQ: IRMD)?
Why did Anthony Vuoto leave IRADIMED's board of directors?
What experience does Joe Kiani bring to IRADIMED's board?
When is Joe Kiani's appointment to IRADIMED's board effective?
What positions will Joe Kiani hold on IRADIMED's board committees?
